Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma

Key Points • Baseline radiomics features accurately predict progression in aggressive B-cell lymphoma.• Radiomics features combined with MYC rearrangement status resulted in the most accurate selection of high-risk patients.

• Publication year

  2022

• Venue

  Blood Advances

• Publication date

  2022-10-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/bloodadvances.2022008629PMID 36306337PMCID 9841040
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index

  2022cited by this paper
• External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients

  2022cited by this paper
• Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.

  2021cited by this paper
• 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma

  2021cited by this paper
• Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis

  2021cited by this paper
• Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review

  2021cited by this paper
• Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?

  2021cited by this paper
• Ceriani L, Gritti G, Cascione L, et al. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Adv. 2020;4(6):1082-1092.

  2020cited by this paper
• Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy

  2020cited by this paper
• SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.

  2020cited by this paper
• Experimental Multicenter and Multivendor Evaluation of the Performance of PET Radiomic Features Using 3-Dimensionally Printed Phantom Inserts

  2020cited by this paper
• Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma

  2020cited by this paper
• Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT.

  2020cited by this paper
• High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP.

  2020cited by this paper
• Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).

  2020cited by this paper
• Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium

  2020cited by this paper
• Corrigendum to 'Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial' [Eur J Canc 124 (January 2020) 25-36].

  2020cited by this paper
• High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma.

  2020cited by this paper
• 18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome

  2019cited by this paper
• RaCaT: An open source and easy to use radiomics calculator tool

  2019cited by this paper
• Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

  2019cited by this paper
• Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

  2019cited by this paper
• Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden

  2019cited by this paper
• Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.

  2019cited by this paper
• Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.

  2019cited by this paper
• Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.

  2019cited by this paper
• Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.

  2019cited by this paper
• Double hit lymphoma: do we need a ‘double hit’ of intensive therapy?

  2018cited by this paper
• Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma

  2018cited by this paper
• Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.

  2018cited by this paper
• Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?

  2017cited by this paper
• Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303

  2016cited by this paper
• The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

  2016cited by this paper
• Prediction models need appropriate internal, internal-external, and external validation.

  2016cited by this paper
• Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable

  2016cited by this paper
• The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping.

  2016cited by this paper
• Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma

  2015cited by this paper
• Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

  2014cited by this paper
• Correcting for Optimistic Prediction in Small Data Sets

  2014cited by this paper
• FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

  2014cited by this paper
• Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.

  2014cited by this paper
• Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

  2014cited by this paper
• Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

  2014cited by this paper
• Clinical Prediction Models

  2013cited by this paper
• The World Health Organization Classification of Lymphoid Neoplasms

  2013influential reference
• Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.

  2010cited by this paper
• MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.

  2009influential reference
• Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

  2004cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper

• Radiogenomics: Current Understandings and Future Perspectives

  2026cites this paper
• Understandings 18 FDG PET radiomics and its application to lymphoma

  2025cites this paper
• Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis

  2025cites this paper
• The Role of Artificial Intelligence and Radiomics in the Management of Lymphomas by PET/CT: The Clairvoyance in Clinic

  2025cites this paper
• Performance of AI methods in PET-based imaging for outcome prediction in lymphoma: A systematic review and meta-analysis.

  2025cites this paper
• Comprehensive DVT risk assessment model for meningioma surgery: development, validation and clinical implementation

  2025cites this paper
• Deep Learning based Stacked Probabilistic Attention Neural Network for the Prediction of Bio Markers in Non-Hodgkin Lymphoma

  2025cites this paper
• Circulating tumor DNA in diffuse large B-cell lymphoma: analysis of response assessment, correlation with PET/CT and clone evolution

  2024cites this paper
• EBF1, PAX5, and MYC: regulation on B cell development and association with hematologic neoplasms

  2024cites this paper
• The value of radiomics features of the spleen as surrogates for differentiating subtypes of common pediatric lymphomas

  2024cites this paper
• PET-based lesion graphs meet clinical data: An interpretable cross-attention framework for DLBCL treatment response prediction

  2024cites this paper
• Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

  2023cites this paper
• Integration of PET in DLBCL.

  2023cites this paper
• Pet-radiomics in lymphoma and multiple myeloma: update of current literature

  2023cites this paper
• Quantitative PET-based biomarkers in lymphoma: getting ready for primetime

  2023cites this paper
• Advances in positron emission tomography and radiomics

  2023cites this paper
• 18F-FDG PET/CT Maximum Tumor Dissemination (Dmax) in Lymphoma: A New Prognostic Factor?

  2023influential citation